The French pharma company confirmed that it expects 2023 business earnings per share–a key metric–to grow low-single digit at constant exchange rates, barring unforeseen major adverse events.
You are here: Home / Top Stories / Dow Jones Newswires: Sanofi backs guidance as it reports higher sales